ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0155

Safety of Bamlanivimab Monotherapy Administered in Dialysis Centers to Hemodialysis Patients for COVID-19

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Mckeon, Katherine L., Davita Clinical Research, Minneapolis, Minnesota, United States
  • Sibbel, Scott, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Wendt, Karl, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Macioce, Nicole, DaVita Inc, Denver, Colorado, United States
  • Tentori, Francesca, Davita Clinical Research, Minneapolis, Minnesota, United States
  • Brunelli, Steven M., Davita Clinical Research, Minneapolis, Minnesota, United States
  • Goykhman, Irina, DaVita Inc, Denver, Colorado, United States
  • Aronoff, George R., DaVita Inc, Denver, Colorado, United States
Background

Bamlanivimab (Eli Lilly) is an intravenously administered monoclonal antibody that was granted an emergency use authorization (EUA) by the US Food and Drug Administration for the treatment of mild to moderate COVID-19 on 09 Nov 2020. On 16 Apr 2021, the EUA was revoked over concerns of resistance among SARS-CoV-2 variants. Between 01 Jan and 16 April 2021, physicians at DaVita dialysis clinics were able to order bamlanivimab (700 mg) treatment during dialysis for nonhospitalized hemodialysis patients who tested positive for SARS-CoV-2 infection and met the eligibility criteria. Here, we report safety data among dialysis patients who received bamlanivimab as a monotherapy for COVID-19.

Methods

Bamlanivimab was administered intravenously as a single dose over the course of 60 minutes during a regularly scheduled hemodialysis session. All patients were monitored for at least 1 hour after bamlanivimab administration. All facilities were required to have emergency medications on-site, and staff were trained to identify and treat potential reactions. A serious adverse event was considered if a patient developed anaphylaxis or any condition requiring use of an epinephrine injection (1:10,000 IM) or albuterol, was sent to the emergency department, or was hospitalized after bamlanivimab administration. An adverse event was considered if a patient developed fever, chills, hives, rash, hypotension, headache, nausea, fatigue, dizziness, angioedema, muscle pain, or throat irritation.

Results

264 patients with newly diagnosed SARS-COV-2 infections received a single dose of bamlanivimab at DaVita. Among all patients who received the drug, 46% were female and the mean age was 60 years. On average, patients were followed for 64 days postinfusion. There were 0 adverse events or serious adverse events documented in the 1-hour postadministration observation window.

Conclusion

Bamlanivimab was found to be safe in dialysis patients.